Narcolepsy
Not recruitingStudy on the Safety and Effectiveness of ALKS 2680 for Patients with Narcolepsy Type 2
- Disease:Narcolepsy
- Substances:Alks 2680
Belgium- Participants:18–64 years · 65+ years
- Substances:Alks 2680
- Sponsor:Alkermes Inc.
Rare diseases
Investigational molecules
Locations
Back to Belgium33 clinical trials in Alken, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.
Belgium
Belgium
Belgium
Belgium
Belgium
Belgium
Belgium
Belgium
BelgiumThe busiest research cities in the country
What the registry says about research in the country
Research focusing on respiratory syncytial virus (RSV) in older adults and chronic sinus conditions, evaluating novel therapeutic approaches for respiratory health.
Investigating immune responses and testing new treatments for nasal congestion and polyp reduction.
Comprehensive studies examining treatments for narcolepsy and sleep disturbances, with particular focus on different narcolepsy types and menopausal sleep issues.
Testing innovative compounds to improve excessive daytime sleepiness and related symptoms.
Advanced research into major depressive disorder and Alzheimer's-related conditions, exploring new therapeutic approaches for complex neuropsychiatric symptoms.
Evaluating novel treatments and combination therapies for better patient outcomes.
Tell us about your condition – we search every trial in Europe and connect you with the right site.